Skip to main content
Clinical Trials/NCT05381077
NCT05381077
Unknown
Not Applicable

Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner

Cliniques universitaires Saint-Luc- Université Catholique de Louvain1 site in 1 country30 target enrollmentFebruary 2, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Myeloma
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Enrollment
30
Locations
1
Primary Endpoint
Evaluation of the diagnostic performance of the different imaging protocols
Last Updated
3 years ago

Overview

Brief Summary

To assess the added value of magnetic resonance imaging (MRI) of the skeleton compared to other validated techniques for the detection of bone lesions in patients with multiple myeloma.

Detailed Description

The aim of our study is to offer patients benefiting from a diagnostic approach to myeloma by PET / CT, a whole body MRI examination (MRI-CE) comprising, in addition to the "classic bone marrow" sequences, a ZTE sequence (see below) . This study is being undertaken to compare and assess the complementarity of imaging techniques in the diagnostic management of this disease. The stages of the work will be: Optimizing bone marrow exploration sequences by MRI (F. Lecouvet, N. Michoux, Gaetan Duchêne). Develop and validate a whole body-wide new MRI sequence "ZTE" capable of detecting and quantifying disease-induced osteolysis in the skeleton. Optimize the reconstruction of these images (Deep Learning software developed with the firm GE), training of the reconstruction of ZTE images by correlation with the scanner (F. Lecouvet, N. Michoux, Gaetan Duchêne). This approach is completely original, never having been evaluated: the ZTE sequence is a recent development, made available at CUSL on the new research MRI magnet. The addition of this sequence to the already major information provided by MRI for the detection of the disease and the evaluation of its response (method of choice, see below) would constitute a major advance in establishing the diagnostic value of this technique. non-irradiating compared to other techniques (PET-CT, low dose scanner, etc.).

Registry
clinicaltrials.gov
Start Date
February 2, 2021
End Date
August 31, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Responsible Party
Principal Investigator
Principal Investigator

Lecouvet

Prof

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Eligibility Criteria

Inclusion Criteria

  • Patient with newly diagnosed multiple myeloma, for whom bone imaging is required for staging.
  • Recurrent patient after intensive treatment (high dose chemotherapy, bone marrow transplant, etc.).
  • Patient requiring a PET / CT considered as the technique of choice in these stages of the disease.

Exclusion Criteria

  • Implanted material incompatible with MRI.
  • Severe claustrophobia.
  • Pregnant women

Outcomes

Primary Outcomes

Evaluation of the diagnostic performance of the different imaging protocols

Time Frame: through study completion, an average of 1 year

The diagnostic performance of the different imaging protocols will be evaluated by analyzing the receptor efficiency function (ROC curve) and by estimating the Sensitivity (Se), Specificity (Sp), Positive Predictive Value (PPV), Negative Predictive Value (NPV) ) as well as the Predictive Accuracy (Acc) of the different imaging protocols.

Comparison of Sensitivity (Se) and Predictive Precision (Acc) of the different imaging protocols

Time Frame: through study completion, an average of 1 year

McNemar test on paired data. The Gold Standard will be determined by a panel of independent experts based on all available imaging techniques.

Study Sites (1)

Loading locations...

Similar Trials